靶向HIF2α-ARNT异二聚化作为肺动脉高压的新治疗策略
该研究在两种临床前肺动脉高压模型中评估新型HIF2α抑制剂PT2567对疾病起始与进展的影响,并进行血流动力学、病理、基因表达和生化分析。结果显示全局抑制HIF2α可改善肺血管血流动力学和重构,PT2567干预降低肺和心脏组织中PH相关靶基因表达并恢复血浆亚硝酸盐浓度,在野百合碱暴露啮齿类中改善心血管血流动力学并提高生存优势。体外实验显示PT2567可减少特发性PAH患者血源性内皮细胞的过度增殖表型和过活跃的精氨酸酶活性。
要点
- HIF2α抑制剂PT2567在两种PH临床前模型中改善肺血管血流动力学和重构。
- PT2567降低肺和心脏PH相关靶基因表达并恢复血浆亚硝酸盐浓度。
- PT2567减少特发性PAH患者内皮细胞过度增殖和精氨酸酶活性。
核心结论
- 靶向HIF2α异二聚化可能为PAH提供新的治疗途径。
研究设计与样本
- 使用两种PH临床前模型评估HIF2α抑制剂PT2567对疾病起始和进展的影响。
- 进行血流动力学测量并收集心脏、肺和血液用于病理、基因表达和生化分析。
- 使用特发性PAH患者血源性内皮细胞评估HIF2α抑制对内皮功能的影响。
主要发现
- 全局抑制HIF2α在su5416/缺氧预防和干预模型中均降低肺血管血流动力学并改善肺血管重构。
- PT2567干预降低肺和心脏组织中PH相关靶基因表达并恢复血浆亚硝酸盐浓度。
- 野百合碱暴露啮齿类接受PT2567治疗后心血管血流动力学影响减轻并获生存优势。
- 体外实验中人肺动脉内皮细胞HIF2α信号缺失抑制炎症相关靶基因,PT2567减少特发性PAH患者血源性内皮细胞过度增殖表型和过活跃精氨酸酶活性。
临床怎么用
- 口服生物利用的HIF2α异二聚化抑制剂可能成为PAH候选治疗策略。
局限性
- 需未来研究确定HIF在异质性PAH人群中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary arterial hypertension (PAH) is a destructive disease of the pulmonary vasculature often leading to right heart failure and death. Current therapeutic intervention strategies only slow disease progression. The role of aberrant hypoxia-inducible factor (HIF)2α stability and function in the initiation and development of pulmonary hypertension (PH) has been an area of intense interest for nearly two decades.Here we determine the effect of a novel HIF2α inhibitor (PT2567) on PH disease initiation and progression, using two pre-clinical models of PH. Haemodynamic measurements were performed, followed by collection of heart, lung and blood for pathological, gene expression and biochemical analysis. Blood outgrowth endothelial cells from idiopathic PAH patients were used to determine the impact of HIF2α-inhibition on endothelial function.Global inhibition of HIF2a reduced pulmonary vascular haemodynamics and pulmonary vascular remodelling in both su5416/hypoxia prevention and intervention models. PT2567 intervention reduced the expression of PH-associated target genes in both lung and cardiac tissues and restored plasma nitrite concentration. Treatment of monocrotaline-exposed rodents with PT2567 reduced the impact on cardiovascular haemodynamics and promoted a survival advantage. In vitro, loss of HIF2α signalling in human pulmonary arterial endothelial cells suppresses target genes associated with inflammation, and PT2567 reduced the hyperproliferative phenotype and overactive arginase activity in blood outgrowth endothelial cells from idiopathic PAH patients. These data suggest that targeting HIF2α hetero-dimerisation with an orally bioavailable compound could offer a new therapeutic approach for PAH. Future studies are required to determine the role of HIF in the heterogeneous PAH population.
引用
- Macias D, Moore S, Crosby A, et al. Targeting HIF2α-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension. Eur Respir J. 2021. PMID: 32972983. doi:10.1183/13993003.02061-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。